<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6841724\results\search\tropicalVirus\results.xml">
  <result pre="naringenin impairs the in vitro infection of human cells by" exact="Zika" post="virus http://orcid.org/0000-0002-3567-7471CataneoAllan Henrique Depieri1KuczeraDiogo1http://orcid.org/0000-0002-3542-1353KoishiAndrea Cristine1ZanlucaCamila1http://orcid.org/0000-0002-1866-0563SilveiraGuilherme Ferreira1http://orcid.org/0000-0001-8015-7152ArrudaThais Bonato de1SuzukawaAndréia Akemi1http://orcid.org/0000-0002-0915-8205BortotLeandro"/>
  <result pre="view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus that belongs to"/>
  <result pre="an arthropod-borne virus that belongs to the Flaviviridae family. The" exact="ZIKV" post="infection is usually asymptomatic or is associated with mild"/>
  <result pre="vaccine nor an antiviral treatment has become available to control" exact="ZIKV" post="replication. Among the natural compounds recognized for their medical"/>
  <result pre="Here, we demonstrate that the citrus flavanone naringenin (NAR) prevented" exact="ZIKV" post="infection in human A549 cells in a concentration-dependent and"/>
  <result pre="NAR and the protease domain of the NS2B-NS3 protein of" exact="ZIKV" post="which could explain the anti-ZIKV activity of NAR. Finally,"/>
  <result pre="developing anti-ZIKV treatments. Subject terms Antivirals Viral infection Introduction The" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus from the Flavivirus"/>
  <result pre="that was first isolated from a rhesus monkey from the" exact="Zika" post="forest of Uganda in 19471. The ZIKV is transmitted"/>
  <result pre="monkey from the Zika forest of Uganda in 19471. The" exact="ZIKV" post="is transmitted primarily by Aedes spp. mosquitoes2. However, transmission"/>
  <result pre="from mother to fetus has also been described3–5. Infection by" exact="ZIKV" post="progresses as a self-limiting disease like observed in dengue"/>
  <result pre="conjunctivitis, myalgia, headache, edema, orbital pain and vomiting6,7. However, during" exact="Zika" post="epidemics in French Polynesia (2013) and Brazil (2015), greater"/>
  <result pre="syndrome (microcephaly) were observed7–9. Strong evidence suggests a link between" exact="ZIKV" post="infection and microcephaly once the viral genome has been"/>
  <result pre="an antiviral drug is available to prevent or treat the" exact="ZIKV" post="infection. Despite recent advances in drug discovery against ZIKV,"/>
  <result pre="fever14–18. Additionally, it was demonstrated that several flavonoids could inhibit" exact="Zika" post="virus infection in vitro and in vivo19–25. The antiviral"/>
  <result pre="similarities between these flaviviruses prompted us to test NAR against" exact="ZIKV" post="infection in vitro. Here, NAR was shown to present"/>
  <result pre="experiments, each one in technical triplicate. In vitro inhibition of" exact="Zika" post="virus infection by NAR is concentration-dependent Based on the"/>
  <result pre="the anti-ZIKV activity of NAR. A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261) and treated with different concentrations of"/>
  <result pre="concentration-dependent (Fig. 2A–C). Surprisingly, IFN-α 2A-treated cells presented more viable" exact="ZIKV" post="particles in the cell culture supernatant than NAR-treated cells"/>
  <result pre="of NAR is concentration-dependent. The A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261; MOI 0.1) for 90 minutes and treated"/>
  <result pre="one-way ANOVA followed by Tukey´s Multiple Comparison Test (*p &amp;lt; 0.05 vs" exact="ZIKV" post="infected and untreated cells and # p &amp;lt; 0.05 vs mock-infected"/>
  <result pre="(Fig. 3A,B). Additionally, RT-qPCR (Fig. 3C) demonstrated that NAR impairs" exact="ZIKV" post="replication. Furthermore, results from two different assays indicate the"/>
  <result pre="Fig. 3). Figure 3 NAR impairs the A549 infection by" exact="Zika" post="virus. A549 cells were infected with ZIKV (ZV BR"/>
  <result pre="A549 infection by Zika virus. A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261; MOI 0.1) and treated with NAR"/>
  <result pre="secondary antibody. (B) The average number of infected-A549 cells. (C)" exact="ZIKV" post="RNA detection in A549 cells by RT-qPCR assay. The"/>
  <result pre="ZIKV RNA detection in A549 cells by RT-qPCR assay. The" exact="ZIKV" post="NS2B RNA was quantified in infected cells compared to"/>
  <result pre="phylogenetic analyses it was demonstrated the existence of two main" exact="Zika" post="virus lineages, the African- and Asian- lineages34. To confirm"/>
  <result pre="Moreover, it was shown that the African- and Asian-lineage of" exact="ZIKV" post="present differences in virulence/pathogenicity in vitro and in vivo37."/>
  <result pre="anti-ZIKV activity of NAR against ZV BR 2015/15261, four additional" exact="ZIKV" post="strains were tested, three from Asian-lineage (ZV BR 2016/16288,"/>
  <result pre="tested, three from Asian-lineage (ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243) and one from African-lineage (ZIKV MR766). Using FACS"/>
  <result pre="NAR impairs the A549-infection with both Asian- and African-lineages of" exact="ZIKV" post="(Fig. 4). However, despite NAR was effective to reduce"/>
  <result pre="despite NAR was effective to reduce the infection with both" exact="ZIKV" post="lineages, a higher effect was observed for Asian-lineage (~4"/>
  <result pre="(Supplementary Fig. 5). Figure 4 NAR impairs the infection of" exact="Zika" post="virus from Asian- and African-lineage in A549 cells. A549"/>
  <result pre="cells. A549 cells were infected with four additional strains of" exact="ZIKV" post="(ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243, ZIKV"/>
  <result pre="additional strains of ZIKV (ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243, ZIKV MR766; MOI 0.1), three from Asian- and"/>
  <result pre="of ZIKV (ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243," exact="ZIKV" post="MR766; MOI 0.1), three from Asian- and one from"/>
  <result pre="were infected with the ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243 and ZIKV MR766 strains. The frequency of A549"/>
  <result pre="the ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243 and" exact="ZIKV" post="MR766 strains. The frequency of A549 cells infected (4G2+)"/>
  <result pre="with the ZV BR 2016/16288 (B), ZV BR 2015/15098 (D)," exact="ZIKV" post="PE243 (F) and ZIKV MR766 (H) strains. Determination of"/>
  <result pre="2016/16288 (B), ZV BR 2015/15098 (D), ZIKV PE243 (F) and" exact="ZIKV" post="MR766 (H) strains. Determination of viable ZIKV in the"/>
  <result pre="PE243 (F) and ZIKV MR766 (H) strains. Determination of viable" exact="ZIKV" post="in the cell culture supernatant of A549 cells infected"/>
  <result pre="infected with ZV BR 2016/16288 (C), ZV BR 2015/15098 (E)," exact="ZIKV" post="PE243 (G) and ZIKV MR766 (I) strains using the"/>
  <result pre="2016/16288 (C), ZV BR 2015/15098 (E), ZIKV PE243 (G) and" exact="ZIKV" post="MR766 (I) strains using the foci-forming immunodetection assay (FFUC6/36/mL)."/>
  <result pre="one-way ANOVA followed by Tukey´s Multiple Comparison Test (*p &amp;lt; 0.05 vs" exact="ZIKV" post="infected and untreated A549 cells). Time of NAR addition"/>
  <result pre="of NAR addition experiments To determine which step of the" exact="ZIKV" post="life cycle NAR exerts its effects, a time of"/>
  <result pre="only after inoculum removal (after infection) seems to impact the" exact="ZIKV" post="infected-A549 cells (Fig. 5B–E). Also, a slightly anti-ZIKV effect"/>
  <result pre="cells. The A549 cells were infected with 0.1 MOI of" exact="ZIKV" post="(ZV BR 2015/15261 strain) and cells were treated with"/>
  <result pre="(2) treated with NAR (125 μM) for 90 minutes prior to" exact="ZIKV" post="infection; (3) treated with NAR during ZIKV infection; (4)"/>
  <result pre="90 minutes prior to ZIKV infection; (3) treated with NAR during" exact="ZIKV" post="infection; (4) treated with NAR during and after ZIKV"/>
  <result pre="during ZIKV infection; (4) treated with NAR during and after" exact="ZIKV" post="infection; (5) treated with NAR after ZIKV infection; or"/>
  <result pre="during and after ZIKV infection; (5) treated with NAR after" exact="ZIKV" post="infection; or (6) treated with IFN-α 2A (200 UI/ml)"/>
  <result pre="infection; or (6) treated with IFN-α 2A (200 UI/ml) after" exact="ZIKV" post="infection as a control of treatment. (B) Representative density"/>
  <result pre="to indicate the potential mechanism of action of flavonoids against" exact="Zika" post="virus24,39. Once the experimental data indicated that NAR could"/>
  <result pre="For validation, two flavonoids known as non-competitive inhibitors of the" exact="ZIKV" post="protease were chosen, namely myricetin, because of its high"/>
  <result pre="calculations show that NAR is able to interact with the" exact="ZIKV" post="protease in a similar way as myricetin and apigenin"/>
  <result pre="we speculate that NAR is able to bind to the" exact="ZIKV" post="protease and inhibit it via a non-competitive mechanism in"/>
  <result pre="(A172) and human embryonic stem cell line (NKX2-5eGFP/whESC). Thus, using" exact="ZIKV" post="strains from Asian- and African-lineage and two different techniques"/>
  <result pre="shown. For antiviral activity of NAR, hmdDCs were infected with" exact="ZIKV" post="(ZV BR 2015/15261 at MOI 10) and treated with"/>
  <result pre="cells in the immune response and its highly susceptibility to" exact="ZIKV" post="infection we decide to test the antiviral activity of"/>
  <result pre="impair the infection of hmdDCs, a key target cell for" exact="ZIKV" post="infection and for the immune system function41,44. Discussion The"/>
  <result pre="ZIKV infection and for the immune system function41,44. Discussion The" exact="Zika" post="virus epidemic in Brazil (2015) was associated with new"/>
  <result pre="flavonoids are able to interact with the NS2B-NS3 protease of" exact="ZIKV" post="through chemical structures, and they play important roles in"/>
  <result pre="different techniques showed that NAR was able to impair the" exact="ZIKV" post="infection in A549 cells. Additionally, we observed that NAR"/>
  <result pre="cells, despite having lower impact on the secretion of viable" exact="ZIKV" post="particles. The same phenotype was observed for A172 and"/>
  <result pre="of type I IFN is needed to reduce 1–2 log of" exact="ZIKV" post="RNA in Vero cell culture supernatant. Finally, this effect"/>
  <result pre="culture supernatant. Finally, this effect seems to be specific for" exact="ZIKV" post="infection, once IFN-α 2A was able to reduce the"/>
  <result pre="context, we tested the antiviral activity of NAR against distinct" exact="ZIKV" post="recent clinical isolates from Asian-lineage obtained from patients in"/>
  <result pre="a higher reduction of infection was observed for Asian-lineages of" exact="ZIKV" post="when compared to the African-lineage. Intrinsic differences in the"/>
  <result pre="in the pathogenicity and virulence of African- and Asian-lineage of" exact="ZIKV" post="were already demonstrated37,60. While those differences could account for"/>
  <result pre="human cell (hmdDCs) NAR seems to be able to impair" exact="ZIKV" post="infection. It was demonstrated that the absorption and metabolism"/>
  <result pre="differential cell-line responses observed62. To determine the stage of the" exact="ZIKV" post="life cycle that is affected by NAR, a time-of-drug-addition"/>
  <result pre="and virus assembly, as already shown for the dengue and" exact="Chikungunya" post="viruses18,63. In addition, the antiviral effect of NAR was"/>
  <result pre="would represent an additional advantage of using NAR for treating" exact="ZIKV" post="infected patients31,32,65,66. The inhibition of viral RNA metabolism occurs"/>
  <result pre="presents anti-ZIKV activity. In vitro NAR was effective against distinct" exact="ZIKV" post="lineages (Asian and African) and seems to act during"/>
  <result pre="results demonstrated that NAR could be a suitable candidate for" exact="ZIKV" post="therapy. Finally, further studies should be undertaken to improve"/>
  <result pre="to establish whether it is effective in vivo. Methods Cells," exact="Zika" post="virus and naringenin Aedes albopictus C6/36 (ATCC: CLR-1660) mosquito"/>
  <result pre="were from Thermo Fisher Scientific (Grand Island, New York, USA)." exact="Zika" post="viruses were isolated from serum of infected patients in"/>
  <result pre="Brazilian National Ethics Committee of Human Experimentation. Additionally, the laboratory-adapted" exact="ZIKV" post="strains ZIKV PE24359 and ZIKV MR7661 were tested. Viral"/>
  <result pre="Ethics Committee of Human Experimentation. Additionally, the laboratory-adapted ZIKV strains" exact="ZIKV" post="PE24359 and ZIKV MR7661 were tested. Viral stocks were"/>
  <result pre="Human Experimentation. Additionally, the laboratory-adapted ZIKV strains ZIKV PE24359 and" exact="ZIKV" post="MR7661 were tested. Viral stocks were grown in C6/36,"/>
  <result pre="were incubated for 18 hours. The cells were then infected with" exact="ZIKV" post="at a multiplicity of infection (MOI) of 0.1 for"/>
  <result pre="Mini Kit, Qiagen, Hilden, Germany) was used to quantify the" exact="ZIKV" post="NS2B genes using a RT-qPCR69. In brief, 5 µg of"/>
  <result pre="In brief, 5 µg of RNA was used to amplify the" exact="ZIKV" post="NS2B gene using specific primers (10 pmol) and a"/>
  <result pre="the RT-PCR assays. Target gene Primer name Sequence (5′–3′) Cycling" exact="Zika" post="virus NS2B gene70 Zika4481 CTGTGGCATGAACCCAATAG 50 °C-30 min 95 °C-15 min"/>
  <result pre="40 cycles 95 °C-15 s 60 °C-30 s 72 °C-1 min 18SR CCCGTCGGCATGTATTAGCT" exact="Zika" post="virus envelope (E) gene72 ZIKVENVF GCTGGDGCRGACACHGGRACT 95 °C-2 min 35"/>
  <result pre="for A549 cells using three different ZIKV-strains (ZV BR 2015/15261;" exact="ZIKV" post="PE243 and ZIKV MR766). The anti-ZIKV activity of NAR"/>
  <result pre="using three different ZIKV-strains (ZV BR 2015/15261; ZIKV PE243 and" exact="ZIKV" post="MR766). The anti-ZIKV activity of NAR in hmdDCs was"/>
  <result pre="assay was performed as described18. In brief, 2 × 106 FFUC6/36 of" exact="ZIKV" post="(ZV BR 2015/15261) was incubated with NAR (125 μM)"/>
  <result pre="μg/mL) (USB-Affymetrix; Santa Clara, CA, USA) at 37 °C for 1 hour." exact="Zika" post="virus RNA samples that were treated with RNase or"/>
  <result pre="untreated were used as controls. After incubation, the amplification of" exact="ZIKV" post="envelope gene was performed based on a one-step RT-PCR"/>
  <result pre="conditions are available in Table 1. Additionally, 2 × 106 FFUC6/36 of" exact="ZIKV" post="was incubated with NAR (125 μM) for 1 h at"/>
  <result pre="(125 μM) for 1 h at 37 °C and residual infectivity of" exact="ZIKV" post="was assessed by foci-forming immunodetection assay in C6/36 as"/>
  <result pre="(2) treated with NAR (125 μM) for 1.5 h prior to" exact="ZIKV" post="infection; (3) treated with NAR during ZIKV infection; (4)"/>
  <result pre="1.5 h prior to ZIKV infection; (3) treated with NAR during" exact="ZIKV" post="infection; (4) treated with NAR during and after ZIKV"/>
  <result pre="during ZIKV infection; (4) treated with NAR during and after" exact="ZIKV" post="infection; (5) treated with NAR after ZIKV infection; or"/>
  <result pre="during and after ZIKV infection; (5) treated with NAR after" exact="ZIKV" post="infection; or (6) treated with IFN-α 2A (200 UI/ml)"/>
  <result pre="infection; or (6) treated with IFN-α 2A (200 UI/ml) after" exact="ZIKV" post="infection as a control of treatment (Fig. 5A). After"/>
  <result pre="for each different treatment. Furthermore, the cells were infected with" exact="ZIKV" post="MOI 0.1 and treated with NAR (125 μM) at"/>
  <result pre="treated with NAR (125 μM) at different time points after" exact="ZIKV" post="infection, namely as 0, 1, 2, 4, 6, and"/>
  <result pre="was the crystallographic structure of the NS2B-NS3 protease from the" exact="ZIKV" post="in a complex with the peptide PDB ID 5GPI76."/>
  <result pre="Hyg.19524650952010.1016/0035-9203(52)90042-412995440 2.LiMWongPSNgLCTanCHOral susceptibility of Singapore Aedes (Stegomya) aegypti (Linnaeus) to" exact="Zika" post="virusPloS. Negl. Trop. Dis.201268e179210.1371/journal.pntd.000179222953014 3.MussoDet al.Potential for Zika virus"/>
  <result pre="(Linnaeus) to Zika virusPloS. Negl. Trop. Dis.201268e179210.1371/journal.pntd.000179222953014 3.MussoDet al.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
  <result pre="2013 to February 2014Euro. Surveill.201419142076110.2807/1560-7917.ES2014.19.14.2076124739982 4.MussoDet al.Potential Sexual Transmission of" exact="Zika" post="VirusEmerg. Infect. Dis.20152123596110.3201/eid2102.14136325625872 5.NoronhaLZanlucaCAzevedoMLVLuzKGDuarte dos SantosCNZika virus damages the"/>
  <result pre="case report, French PolynesiaEuro. Surveill.20141991310.2807/1560-7917.ES2014.19.9.20720 9.CalvetGet al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
  <result pre="alterações no crescimento e desenvolvimento relacionadas à infecção pelo vírus" exact="Zika" post="e outras etiologias infecciosas, até a Semana Epidemiológica 15"/>
  <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 17 de 2018 http://portalarquivos2.saude.gov.br/images/pdf/2018/junho/11/2018-022.pdf (2018)."/>
  <result pre="de 2018 http://portalarquivos2.saude.gov.br/images/pdf/2018/junho/11/2018-022.pdf (2018). 12.SaizJCMartín-AcebesMAThe Race To Find Antivirals for" exact="Zika" post="VirusAntimicrob. Agents Chemother.2017616e004111710.1128/AAC.00411-1728348160 13.HavsteenBFlavonoids, a class of natural products"/>
  <result pre="in human cellsSci. Rep.201774186410.1038/srep4186428157234 19.CarneiroBMBatistaMNBragaACSNogueiraMLRahalPThe green tea molecule EGCG inhibits" exact="Zika" post="virus entryVirol.201649621521810.1016/j.virol.2016.06.012 20.WongGet al.Antivrial activity of quercetin-3-b-O-D-glucosidase against Zika"/>
  <result pre="inhibits Zika virus entryVirol.201649621521810.1016/j.virol.2016.06.012 20.WongGet al.Antivrial activity of quercetin-3-b-O-D-glucosidase against" exact="Zika" post="virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts Dengue and"/>
  <result pre="quercetin-3-b-O-D-glucosidase against Zika virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts" exact="Dengue" post="and Zika Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet"/>
  <result pre="Zika virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts Dengue and" exact="Zika" post="Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins"/>
  <result pre="Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins Inhibit" exact="Dengue" post="and Zika Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin"/>
  <result pre="via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins Inhibit Dengue and" exact="Zika" post="Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin Precludes Initiation"/>
  <result pre="Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin Precludes Initiation of" exact="Zika" post="Virus Infection in Human CellsInt. J. Mol. Sci.2018194E109310.3390/ijms1904109329621184 24.OoATeohBTSamSSBakarSAZandiKBaicalein"/>
  <result pre="in Human CellsInt. J. Mol. Sci.2018194E109310.3390/ijms1904109329621184 24.OoATeohBTSamSSBakarSAZandiKBaicalein and baicalin as" exact="Zika" post="virus inhibitorsArch. Virol.2019164258559310.1007/s00705-018-4083-430392049 25.LeeJLLoeMWCLeeRCHChuJJHAntiviral activity of pinocembrin against Zika"/>
  <result pre="as Zika virus inhibitorsArch. Virol.2019164258559310.1007/s00705-018-4083-430392049 25.LeeJLLoeMWCLeeRCHChuJJHAntiviral activity of pinocembrin against" exact="Zika" post="virus replicationAntiviral Res.2019167132410.1016/j.antiviral.2019.04.00330959074 26.de SousaLRFet al.Flavonoids as noncompetitive inhibitors"/>
  <result pre="virus replicationAntiviral Res.2019167132410.1016/j.antiviral.2019.04.00330959074 26.de SousaLRFet al.Flavonoids as noncompetitive inhibitors of" exact="Dengue" post="virus NS2B-NS3 protease: Inhibition kinetics and docking studiesBioorganic Med."/>
  <result pre="Inhibition kinetics and docking studiesBioorganic Med. Chem.20152346647010.1016/j.bmc.2014.12.015 27.RoyALimLSrivastavaSLuYSongJSolution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
  <result pre="Signaling PathwayPloS One2016114e015301510.1371/journal.pone.015301527045367 33.FrumenceEet al.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
  <result pre="to IFN-b production and apoptosis inductionVirology201649321722610.1016/j.virol.2016.03.00627060565 34.HaddowADet al.Genetic Characterization of" exact="Zika" post="Virus Strains: Geographic Expansion of the Asian LineagePLoS Negl."/>
  <result pre="LineagePLoS Negl. Trop. Dis.201262e147710.1371/journal.pntd.000147722389730 35.LanciottiRSet al.Genetic and Serologic Properties of" exact="Zika" post="Virus Associated with an Epidemic, Yap State, Micronesia, 2007Emerg."/>
  <result pre="State, Micronesia, 2007Emerg. Infect. Dis.20081481232123910.3201/eid1408.08028718680646 36.BinghamAMConeMMockVComparison of Test Results for" exact="Zika" post="Virus RNA in Urine, Serum, and Saliva Specimens from"/>
  <result pre="in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated" exact="Zika" post="Virus Disease – Florida, 2016MMWR Morb Mortal Wkly Rep.20166518475810.15585/mmwr.mm6518e227171533"/>
  <result pre="Rep.20166518475810.15585/mmwr.mm6518e227171533 37.SimoninYRielDVde PerrePVRockxBSalinasSDifferential virulence between Asian and African lineages of" exact="Zika" post="virusPLoS Negl. Trop. Dis.2017119e000582110.1371/journal.pntd.000582128934211 38.DaelemansDPauwelsRDe ClercqEPannecouqueCA time-of-drug addition approach"/>
  <result pre="requirements and prediction of inhibitory activity of natural flavonoids against" exact="Zika" post="virus through molecular docking and Monte Carlos based QSAR"/>
  <result pre="Virus Associated with MicrocephalyN. Engl. J. Med.2016374951810.1056/NEJMoa160065126862926 41.HamelRet al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015891788809610.1128/JVI.00354-1526085147 42.SunXet al.Transcriptional"/>
  <result pre="Human Skin CellsJ. Virol.2015891788809610.1128/JVI.00354-1526085147 42.SunXet al.Transcriptional Changes during Naturally Acquired" exact="Zika" post="Virus Infection Render Dendritic Highly Conductive to Viral ReplicationCell"/>
  <result pre="of human dendritic cells by African and Asian strains of" exact="Zika" post="virusSci. Rep.201881544010.1038/s41598-018-23734-329615676 44.Reis e SouzaCActivation of dendritic cells: translating"/>
  <result pre="Opin. Immunol.200416121510.1016/j.coi.2003.11.00714734106 45.WahidBAliARafiqueSIdreesMCurrent status of therapeutic and vaccine approaches against" exact="Zika" post="virusEur. J. Intern. Med.201744121810.1016/j.ejim.2017.08.00128797534 46.Pires de MelloCPet al.Zika virus"/>
  <result pre="48.ZandiKTeohBSamSWongPMustafaMRIn vitro antiviral activity of Fisetin, Rutin and Naringenin against" exact="Dengue" post="virus type-2J. Med. Plants Res.2011555345539 49.ZhangTet al.Anti-Japanese-encephalitis-viral effects of"/>
  <result pre="al.A sensitive virus yield assay for evaluation of Antiviral against" exact="Zika" post="VirusJ. Virol. Meth.2016238132010.1016/j.jviromet.2016.09.015 57.SchneiderWHChevillotteMDRiceCMInterferon-Stimulated Genes: A Complex Web of"/>
  <result pre="DefensesAnn. Rev. Immunol.20143251354510.1146/annurev-immunol-032713-12023124555472 58.ZanlucaCet al.First report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem. Inst. Oswaldo Cruz2015110456957210.1590/0074-0276015019226061233 59.DonaldCLet al.Full Genome"/>
  <result pre="59.DonaldCLet al.Full Genome Sequence and sfRNA Interferon Antagonist Activity of" exact="Zika" post="Virus from Recife, BrazilPLoS Negl Trop Dis.2016510e000504810.1371/journal.pntd.0005048 60.SheridanMAet al.African"/>
  <result pre="BrazilPLoS Negl Trop Dis.2016510e000504810.1371/journal.pntd.0005048 60.SheridanMAet al.African and Asian strains of" exact="Zika" post="virus differ in their ability to infect and lyse"/>
  <result pre="al.Inhibitors of alphavirus entry and replication identified with a stable" exact="Chikungunya" post="replicon cell line and virus-based assaysPLoS One2011612e2892310.1371/journal.pone.002892322205980 64.Valério De"/>
  <result pre="2(-Delta Delta C(T)) methodMethods20012540240810.1006/meth.2001.126211846609 71.StrottmannDMet al.Genetic and biological characterization of" exact="Zika" post="virus isolates from different Brazilian regionsMem. Inst. Osw. Cruz2019114e19015010.1590/0074-02760190150"/>
  <result pre="regionsMem. Inst. Osw. Cruz2019114e19015010.1590/0074-02760190150 72.FayeOet al.One-step RT-PCR for detection of" exact="Zika" post="virusJ. Clin. Virol.20084319610110.1016/j.jcv.2008.05.00518674965 73.TrottOOlsonAAutoDock Vina: improving the speed and"/>
  <result pre="Mol. Model.20131913210.1007/s00894-012-1667-x23187683 76.ZhangZet al.Crystal structure of unlinked NS2B-NS3 protease from" exact="Zika" post="virusScience.201635463191597160010.1126/science.aai930927940580 77.Van Der SpoelDet al.GROMACS: Fast, flexible, and freeJ."/>
 </snippets>
</snippetsTree>
